Lazard Asset Management LLC Purchases New Position in Cryoport, Inc. (NASDAQ:CYRX)

Lazard Asset Management LLC acquired a new stake in Cryoport, Inc. (NASDAQ:CYRX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,558 shares of the company’s stock, valued at approximately $51,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Quarry LP purchased a new stake in shares of Cryoport during the 4th quarter valued at about $69,000. Nebula Research & Development LLC grew its position in Cryoport by 21.6% in the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after acquiring an additional 2,207 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Cryoport by 135.5% during the fourth quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock valued at $100,000 after purchasing an additional 7,407 shares during the period. Olympiad Research LP purchased a new stake in shares of Cryoport during the fourth quarter valued at approximately $103,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Cryoport during the fourth quarter valued at approximately $111,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Stock Performance

Shares of Cryoport stock opened at $6.04 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $11.64. The firm’s 50-day simple moving average is $5.93 and its 200-day simple moving average is $6.81. The firm has a market cap of $302.83 million, a PE ratio of -1.79 and a beta of 1.92.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The firm had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million. Equities analysts forecast that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Activity

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the transaction, the chief executive officer now owns 765,399 shares of the company’s stock, valued at $4,814,359.71. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders sold 19,830 shares of company stock worth $118,353. 10.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CYRX. Roth Mkm restated a “buy” rating and issued a $15.00 target price on shares of Cryoport in a research note on Tuesday, April 1st. UBS Group upped their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Thursday, May 8th. Morgan Stanley dropped their target price on Cryoport from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Monday, May 5th. Finally, Guggenheim reissued a “buy” rating and issued a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Cryoport presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.